High Times
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, $Pistol Pete$
Search This Board: 
Last Post: 10/19/2018 5:52:41 PM - Followers: 421 - Board type: Free - Posts Today: 0


     WEEKLY NUMBERS     http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116919069
Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf


Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mnkd.proboards.com/  A good forum for discussion on Mankind


MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.





High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Current Report Filing (8-k) 10/16/2018 05:00:01 PM
MNKD News: United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement 10/16/2018 06:00:00 AM
MNKD News: United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement 10/16/2018 06:00:00 AM
MNKD News: Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity 10/15/2018 09:00:00 AM
MNKD News: MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Stud... 10/04/2018 09:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#30134  Sticky Note $MNKD Early Insulin Therapy for Type 2 testing $Pistol Pete$ 09/03/18 12:26:56 PM
#27521  Sticky Note From the MNKD proboards -->> TTIME 02/14/18 02:49:38 PM
#31114   Lookin good lets Go! Profit 10/19/18 05:52:41 PM
#31113   MNKD Weekly Chart conix 10/19/18 05:06:09 PM
#31111   Shorts about to get creamed Moby Dick 10/19/18 12:55:20 PM
#31109   Like you I was here then still here Profit 10/19/18 11:42:41 AM
#31108   This same discussion was had 5 years ago SidVicious 10/19/18 11:24:10 AM
#31107   In 10 years it could be 10 x10 Profit 10/19/18 11:10:04 AM
#31106   Anything can happen but I don't believe it SidVicious 10/19/18 11:09:47 AM
#31105   ARE YOU PAYING ENOUGH ATTENTION TO MANKIND? WallStreetSTTA 10/19/18 09:57:19 AM
#31104   Sid: Really? You think it can't happen? Want Go4itbigtime 10/19/18 09:28:59 AM
#31103   Yeah, in about 5to 10 years SidVicious 10/19/18 09:04:27 AM
#31102   I agree..possibly a 10 bagger Go4itbigtime 10/19/18 08:50:11 AM
#31101   Patience people, accumulating shares here. Easily pop to harry crumb 10/19/18 08:44:06 AM
#31100   Doctors don’t take Columbus Day off. I know SidVicious 10/19/18 08:39:55 AM
#31099   For a short week, scrip numbers are way WallStreetSTTA 10/19/18 08:08:30 AM
#31098   "NEW SCRIPT NUMBERS: parkourstar 10/19/18 07:50:00 AM
#31097   Shorts are now on the danger side of STOCKSEEK 10/19/18 12:47:24 AM
#31096   I got back in at $1.52 two weeks lakingsphan0427 10/18/18 06:01:20 PM
#31094   * * $MNKD Video Chart 10-18-18 * * ClayTrader 10/18/18 05:07:05 PM
#31093   I agree and just about as much as STOCKSEEK 10/18/18 11:40:21 AM
#31092   His charts are a joke. He's 20/20 hindsight. SidVicious 10/18/18 11:16:27 AM
#31091   Time for 2’s like I said yesterday - STOCKSEEK 10/18/18 10:40:04 AM
#31090   Here we goooooooooo Go4itbigtime 10/18/18 10:39:38 AM
#31089   We have been getting positive articles popping up WallStreetSTTA 10/18/18 09:41:28 AM
#31088   Why is clay so interested in mnkd...two postings Go4itbigtime 10/17/18 05:23:18 PM
#31087   * * $MNKD Video Chart 10-17-18 * * ClayTrader 10/17/18 04:58:00 PM
#31086   It is how to make money and enjoy $Pistol Pete$ 10/17/18 03:37:51 PM
#31085   At this point just cleaning up the under STOCKSEEK 10/17/18 03:03:21 PM
#31084   Why so quiet? Investment not panning out? SidVicious 10/17/18 02:10:34 PM
#31083   However, if new +news comes out today, we Go4itbigtime 10/17/18 10:02:55 AM
#31082   Damn..Clay had to post...down today Go4itbigtime 10/17/18 08:53:16 AM
#31081   Okay PP, I'm learning from you..will know how Go4itbigtime 10/17/18 08:50:36 AM
#31080   Nice close $Pistol Pete$ 10/17/18 01:50:34 AM
#31079   * * $MNKD Video Chart 10-16-18 * * ClayTrader 10/16/18 05:24:42 PM
#31078   Was that Parky loading up today ? TTIME 10/16/18 04:07:19 PM
#31077   MNKD heating up again!? Nice 16% green here theStockGAMEoOo 10/16/18 03:28:34 PM
#31076   NICE!!!! More to come I believe... Go4itbigtime 10/16/18 12:46:46 PM
#31075   Deal was already done. Stop while you can. SidVicious 10/16/18 09:24:32 AM
#31074   UTHR 8K FILLING OUT AND MNKD ANNOUNCE THE WallStreetSTTA 10/16/18 08:16:56 AM
#31073   Deals Sealed Lets GO! $MNKD$ Profit 10/16/18 07:08:43 AM
#31072   Well, first, it is quoted in Brazilan reals: parkourstar 10/15/18 05:17:58 PM
#31071   "MannKind finished the week of October 5th with parkourstar 10/15/18 04:47:43 PM
#31070   Not to small..400 mill market cap TTIME 10/15/18 05:26:28 AM
#31069   Yeah, it was submitted a year ago -- parkourstar 10/14/18 10:30:29 AM
#31068   Lol... You’re hilarious. Drama. You’re soon going to STOCKSEEK 10/13/18 06:08:18 PM
#31067   What are you talking about,Q4 is now, approval TTIME 10/13/18 10:19:11 AM
#31066   WHAT! They had to do it again!?!?! Why? SidVicious 10/12/18 08:32:52 PM
#31065   I like you anyway:) I'm strong in at LUPO BIANCO 10/12/18 07:53:24 PM
#31064   YOU are the King SPIN DOCTOR! TTIME 10/12/18 11:15:11 AM
#31063   Afrezza has been submitted to ANVISA in Brazil WallStreetSTTA 10/12/18 10:45:00 AM
#31062   "NEW SCRIPT NUMBERS: parkourstar 10/12/18 09:55:32 AM